

Guy Boivin

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/8630293/publications.pdf](https://exaly.com/author-pdf/8630293/publications.pdf)

Version: 2025-02-01

339

peer-reviewed
articles

15,576

peer-reviewed
citations

14457

66

peer-reviewed
h-index

21372

121

g-index

371

documents

18591

doc citations

14022

72

h-index

24447

citing authors

#	ARTICLE	IF	CITATIONS
1	Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012–2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network. <i>Open Forum Infectious Diseases</i> , 2025, 12, .	0.8	7
2	Influenza A virus interferes with respiratory syncytial virus in mice and reconstituted human airway epithelium. <i>Microbiology Spectrum</i> , 2025, 13, .	3.6	3
3	Viral Interference and Coinfections: A Perspective From Hospital Surveillance of Respiratory Viruses. <i>Journal of Medical Virology</i> , 2025, 97, .	3.7	3
4	Vaccine Development for Human Pneumoviruses. <i>Vaccines</i> , 2025, 13, 569.	2.9	9
5	In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2. <i>Viruses</i> , 2025, 17, 941.	3.2	0
6	Long COVID Symptom Management Through Self-Care and Nonprescription Treatment Options: A Narrative Review. <i>International Journal of Environmental Research and Public Health</i> , 2025, 22, 1362.	2.9	1
7	Impact of COVID-19 and Vaccination During Pregnancy on Placenta-Mediated Complications (COVIGRO) Tj ETQq1 1 0.784314 rgBT / Ov 0,9 3	0.9	3
8	Herpes Simplex Virus 1 Infection Does Not Increase Amyloid- β Pathology in APP/PS1 Mice. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 171-178.	2.6	5
9	The impact of trained immunity in respiratory viral infections. <i>Reviews in Medical Virology</i> , 2024, 34, .	6.8	5
10	Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir. <i>Infectious Disease Reports</i> , 2024, 16, 65-82.	2.4	20
11	A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses. <i>Journal of Medical Virology</i> , 2024, 96, .	3.7	5
12	Viral interference between severe acute respiratory syndrome coronavirus 2 and influenza A viruses. <i>PLoS Pathogens</i> , 2024, 20, e1012017.	4.4	27
13	Viral Loads of Pneumoviruses: Correlation With Coinfection Rates and Disease Severity. <i>Journal of Medical Virology</i> , 2024, 96, .	3.7	2
14	Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study. <i>BMJ Open</i> , 2023, 13, e067640.	1.9	4
15	Treatment of COVID-19 symptoms with over the counter (OTC) medicines used for treatment of common cold and flu. <i>Clinical Infection in Practice</i> , 2023, 19, 100230.	0.4	8
16	Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs. <i>Microorganisms</i> , 2023, 11, 1095.	3.8	4
17	In vitro fitness of SARS-CoV-2 variants as assessed by competition experiments followed by ddRT-PCR and whole genome sequencing. <i>Journal of Clinical Virology</i> , 2023, 165, 105517.	3.1	5
18	In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. <i>Virology</i> , 2023, 586, 115-121.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	3.4	5
20	The possibility of spreading herpes simplex virus type 1 via food handling and sharing. <i>Journal of Applied Microbiology</i> , 2023, 134, .	3.2	2
21	Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 116, 387-390.	2.1	4
22	Viral Interference between Respiratory Viruses. <i>Emerging Infectious Diseases</i> , 2022, 28, 273-281.	3.8	267
23	Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells. <i>Viruses</i> , 2022, 14, 395.	3.2	53
24	Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response. <i>Journal of Neuroinflammation</i> , 2022, 19, .	9.0	28
25	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. <i>Vaccine</i> , 2022, 40, 2635-2646.	3.1	12
26	The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 916-925.	3.4	22
27	In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes. <i>Antiviral Research</i> , 2022, 202, 105328.	3.8	6
28	Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid. <i>Pathogens</i> , 2022, 11, 1048.	3.0	6
29	A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice. <i>Biomedicines</i> , 2022, 10, 2516.	3.4	13
30	Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples. <i>Journal of Infectious Diseases</i> , 2021, 223, 1052-1061.	3.8	7
31	Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review. <i>Reviews in Medical Virology</i> , 2021, 31, .	6.8	11
32	RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions. <i>Viruses</i> , 2021, 13, 139.	3.2	49
33	Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases. <i>Antiviral Research</i> , 2021, 188, 105046.	3.8	3
34	Genetics of symptom remission in outpatients with COVID-19. <i>Scientific Reports</i> , 2021, 11, .	3.4	7
35	Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	4.1	13
36	Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. <i>ACS Omega</i> , 2021, 6, 16584-16591.	4.2	22

#	ARTICLE	IF	CITATIONS
37	Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes. <i>PLoS ONE</i> , 2021, 16, e0253022.	2.3	20
38	Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice. <i>Journal of Neuroinflammation</i> , 2021, 18, .	9.0	28
39	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	23.4	253
40	A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis. <i>Scientific Reports</i> , 2021, 11, .	3.4	6
41	High and low flowrate sampling of airborne influenza in hospital rooms during three outbreaks. <i>Journal of Aerosol Science</i> , 2021, 158, 105824.	2.9	4
42	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , 2021, 11, .	3.9	585
43	Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.. <i>Journal of General Virology</i> , 2021, 102, .	3.3	7
44	Avian Cell Line DuckCelt [®] -T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac [®] . <i>Vaccines</i> , 2021, 9, 1190.	2.9	14
45	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls. <i>Clinical Infectious Diseases</i> , 2020, 71, 1438-1446.	5.2	47
46	Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. <i>Vaccine</i> , 2020, 38, 278-287.	3.1	13
47	In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. <i>Viruses</i> , 2020, 12, 1139.	3.2	34
48	An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis. <i>Journal of Virology</i> , 2020, 94, .	3.6	35
49	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. <i>Microorganisms</i> , 2020, 8, 1968.	3.8	10
50	Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	4.1	4
51	Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. <i>Antiviral Research</i> , 2020, 179, 104807.	3.8	20
52	Engineering of Live Chimeric Vaccines against Human Metapneumovirus. <i>Pathogens</i> , 2020, 9, 135.	3.0	22
53	Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	16.8	100
54	Modified cyclodextrins as broad-spectrum antivirals. <i>Science Advances</i> , 2020, 6, .	10.9	183

#	ARTICLE	IF	CITATIONS
55	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 428-437.	3.8	46
56	Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice. <i>Vaccine</i> , 2020, 38, 2122-2127.	3.1	16
57	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. <i>Journal of Infectious Diseases</i> , 2019, 219, 365-374.	3.8	15
58	Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. <i>Scientific Reports</i> , 2019, 9, .	3.4	42
59	The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. <i>Antiviral Research</i> , 2019, 170, 104561.	3.8	3
60	<i>Streptococcus pneumoniae</i> serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). <i>Vaccine</i> , 2019, 37, 5466-5473.	3.1	39
61	Antiviral Agents in Development for Zika Virus Infections. <i>Pharmaceuticals</i> , 2019, 12, 101.	4.2	67
62	Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development. <i>Vaccines</i> , 2019, 7, 164.	2.9	19
63	Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. <i>Scientific Reports</i> , 2019, 9, .	3.4	18
64	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , 2019, 155, 69-78.	1.0	91
65	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , 2019, 163, 91-105.	3.8	99
66	OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes. <i>Npj Vaccines</i> , 2019, 4, .	5.3	37
67	Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. <i>Journal of Infectious Diseases</i> , 2019, 220, 1302-1306.	3.8	17
68	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. <i>Emerging Infectious Diseases</i> , 2019, 25, 838-840.	3.8	7
69	Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 609.	2.9	7
70	Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice. <i>PLoS Pathogens</i> , 2019, 15, e1007689.	4.4	27
71	Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. <i>Frontiers in Immunology</i> , 2019, 10, .	4.9	58
72	The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2019, 25, 372-383.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Novel antiviral compounds and combination therapy for influenza viruses. <i>Virologie</i> , 2019, 23, 32-35.	0.2	0
74	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. <i>PLoS Pathogens</i> , 2019, 15, e1008168.	4.4	23
75	Influenza virus epidemiology: a permanent vaccine challenge. <i>Virologie</i> , 2019, 23, 271-276.	0.2	0
76	The Nonstructural NS1 Protein of Influenza Viruses Modulates TP53 Splicing through Host Factor CPSF4. <i>Journal of Virology</i> , 2019, 93, .	3.6	27
77	In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors. <i>Viruses</i> , 2019, 11, 6.	3.2	10
78	Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. <i>Journal of Infectious Diseases</i> , 2019, 221, 63-70.	3.8	61
79	Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient. <i>Antiviral Therapy</i> , 2019, 24, 581-587.	1.9	6
80	HUMAN PARAINFLUENZA 2 RELATED ILLNESS AND A DEATH IN A GROUP OF CAPTIVE WESTERN LOWLAND GORILLAS (GORILLA GORILLA GORILLA). <i>Journal of Zoo and Wildlife Medicine</i> , 2019, 50, 713.	0.6	0
81	Novel antiviral compounds and combination therapy for influenza viruses. <i>Virologie</i> , 2019, 23, 325-328.	0.2	0
82	Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , 2018, 154, 110-115.	3.8	7
83	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). <i>Vaccine</i> , 2018, 36, 2166-2175.	3.1	58
84	Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. <i>British Journal of Pharmacology</i> , 2018, 175, 388-403.	6.3	21
85	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 232-240.	3.4	33
86	Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. <i>Viruses</i> , 2018, 10, 610.	3.2	29
87	Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models. <i>Antiviral Research</i> , 2018, 159, 26-34.	3.8	3
88	The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2563-2574.	3.6	23
89	Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2018, 24, 761-768.	1.6	28
90	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. <i>Journal of General Virology</i> , 2018, 99, 209-218.	3.3	9

#	ARTICLE	IF	CITATIONS
91	Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. <i>Journal of General Virology</i> , 2018, 99, 1367-1380.	3.3	6
92	Herpesvirus DNA polymerases: Structures, functions and inhibitors. <i>Virus Research</i> , 2017, 234, 177-192.	2.6	81
93	Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration. <i>Journal of Virology</i> , 2017, 91, .	3.6	32
94	DNA vaccination protects mice against Zika virus-induced damage to the testes. <i>Nature Communications</i> , 2017, 8, .	13.7	99
95	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. <i>Vaccine</i> , 2017, 35, 3647-3654.	3.1	30
96	Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	4.1	20
97	A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. <i>Open Forum Infectious Diseases</i> , 2017, 4, .	0.8	47
98	The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus. <i>Journal of Medical Virology</i> , 2017, 89, 2239-2243.	3.7	10
99	The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. <i>Antiviral Research</i> , 2017, 137, 6-13.	3.8	11
100	Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies. <i>Journal of Medical Virology</i> , 2017, 89, 737-741.	3.7	3
101	Single Dose IV Peramivir Treatment in Pediatric Influenza: Lack of Development of Influenza Virus Variants with Reduced Susceptibility to Peramivir. <i>Open Forum Infectious Diseases</i> , 2017, 4, S520-S520.	0.8	0
102	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. <i>Journal of Infectious Diseases</i> , 2017, 216, 405-414.	3.8	158
103	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. <i>BMC Infectious Diseases</i> , 2017, 17, .	2.6	22
104	Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis. <i>Journal of General Virology</i> , 2017, 98, 447-460.	3.3	14
105	Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia. <i>Journal of General Virology</i> , 2017, 98, 1174-1180.	3.3	15
106	In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site. <i>Journal of General Virology</i> , 2017, 98, 1224-1231.	3.3	13
107	A Cluster of Three Cases of Hantavirus Pulmonary Syndrome among Canadian Military Personnel. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-4.	4.9	6
108	Factors Associated With Antibiotic Exposure in Children Less Than 3 Years Old Hospitalized With Bronchiolitis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.8	0

#	ARTICLE	IF	CITATIONS
109	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. <i>Journal of the American Chemical Society</i> , 2016, 138, 16212-16215.	15.0	58
110	Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 654-662.	3.4	146
111	The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models. <i>Antiviral Research</i> , 2016, 132, 6-12.	3.8	17
112	A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. <i>Biologicals</i> , 2016, 44, 242-251.	1.4	109
113	Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 122-126.	3.4	5
114	Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2120-2127.	4.0	35
115	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. <i>Vaccine Journal</i> , 2016, 23, 236-242.	3.1	73
116	Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice. <i>PLoS ONE</i> , 2016, 11, e0168034.	2.3	9
117	Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies. <i>Reviews in Medical Virology</i> , 2015, 25, 300-319.	6.8	39
118	Effect of In Vitro Syncytium Formation on the Severity of Human Metapneumovirus Disease in a Murine Model. <i>PLoS ONE</i> , 2015, 10, e0120283.	2.3	15
119	Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis. <i>PLoS ONE</i> , 2015, 10, e0145773.	2.3	31
120	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2015, 212, 1726-1734.	3.8	63
121	Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility. <i>Journal of Virology</i> , 2015, 89, 4636-4644.	3.6	15
122	Intrahost Dynamics of Antiviral Resistance in Influenza A Virus Reflect Complex Patterns of Segment Linkage, Reassortment, and Natural Selection. <i>MBio</i> , 2015, 6, .	4.4	66
123	Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. <i>Journal of General Virology</i> , 2015, 96, 767-774.	3.3	22
124	Heterosubtypic Protection Conferred by the Human Monoclonal Antibody PN-SIA28 against Influenza A Virus Lethal Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2647-2653.	4.1	3
125	Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations. <i>Journal of Virological Methods</i> , 2015, 224, 58-66.	1.7	132
126	Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. <i>Antiviral Research</i> , 2015, 123, 105-113.	3.8	43

#	ARTICLE	IF	CITATIONS
127	Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. <i>Journal of Virological Methods</i> , 2015, 225, 1-3.	1.7	13
128	Targeted Proteomics of Human Metapneumovirus in Clinical Samples and Viral Cultures. <i>Analytical Chemistry</i> , 2015, 87, 10247-10254.	6.5	36
129	Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains. <i>Antiviral Research</i> , 2015, 114, 57-61.	3.8	17
130	Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. <i>PLoS ONE</i> , 2015, 10, e0126115.	2.3	54
131	Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1219-1226.	3.8	35
132	Antiviral drug resistance in herpesviruses other than cytomegalovirus. <i>Reviews in Medical Virology</i> , 2014, 24, 186-218.	6.8	144
133	Oseltamivir+zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , 2014, 105, 54-58.	3.8	15
134	Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus In Vitro, in Mice and in Ferrets. <i>Journal of Virology</i> , 2014, 88, 1652-1658.	3.6	52
135	Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. <i>Vaccine</i> , 2014, 32, 5730-5739.	3.1	16
136	Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6398-6405.	4.1	31
137	Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants. <i>Journal of General Virology</i> , 2014, 95, 2377-2389.	3.3	17
138	Characterization of Drug-Resistant Influenza Virus A(H1N1) and A(H3N2) Variants Selected In Vitro with Laninamivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5220-5228.	4.1	50
139	Human metapneumovirus viral load is an important risk factor for disease severity in young children. <i>Journal of Clinical Virology</i> , 2014, 60, 133-140.	3.1	36
140	Randomized Controlled Ferret Study to Assess the Direct Impact of 2008-09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. <i>PLoS ONE</i> , 2014, 9, e86555.	2.3	23
141	Recent developments with live-attenuated recombinant paramyxovirus vaccines. <i>Reviews in Medical Virology</i> , 2013, 23, 15-34.	6.8	25
142	Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. <i>Journal of Clinical Virology</i> , 2013, 58, 541-547.	3.1	48
143	Host and Viral Factors Affecting Clinical Performance of a Rapid Diagnostic Test for Respiratory Syncytial Virus in Hospitalized Children. <i>Journal of Pediatrics</i> , 2013, 163, 911-913.	2.0	26
144	Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. <i>Journal of Clinical Virology</i> , 2013, 58, 279-282.	3.1	15

#	ARTICLE	IF	CITATIONS
145	Influenza virus resistance to neuraminidase inhibitors. <i>Antiviral Research</i> , 2013, 98, 174-185.	3.8	332
146	Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. <i>Vaccine</i> , 2013, 31, 2778-2785.	3.1	48
147	Detection and management of antiviral resistance for influenza viruses. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 18-23.	3.4	57
148	The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2013, 100, 649-653.	3.8	19
149	Both TRIF and IPS-1 Adaptor Proteins Contribute to the Cerebral Innate Immune Response against Herpes Simplex Virus 1 Infection. <i>Journal of Virology</i> , 2013, 87, 7301-7308.	3.6	38
150	Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1784-1789.	4.1	15
151	Novel Method Based on <i>En Passant</i> Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3216-3224.	4.0	30
152	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e72529.	2.3	33
153	Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children. <i>Journal of Infectious Diseases</i> , 2012, 206, 178-189.	3.8	155
154	Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v). <i>Journal of Infectious Diseases</i> , 2012, 206, 1852-1861.	3.8	86
155	Presence of Oseltamivir-Resistant Pandemic A/H1N1 Minor Variants Before Drug Therapy With Subsequent Selection and Transmission. <i>Journal of Infectious Diseases</i> , 2012, 206, 1504-1511.	3.8	72
156	Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice. <i>Vaccine Journal</i> , 2012, 19, 209-218.	3.1	46
157	The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets. <i>Journal of Virology</i> , 2012, 86, 10651-10660.	3.6	106
158	Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4375-4380.	4.1	17
159	Impact of deficiency in CCR2 and CX3CR1 receptors on monocytes trafficking in herpes simplex virus encephalitis. <i>Journal of General Virology</i> , 2012, 93, 1294-1304.	3.3	30
160	Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2012, 96, 414-421.	3.8	26
161	Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. <i>Journal of Clinical Virology</i> , 2012, 53, 88-92.	3.1	27
162	Ten years of human metapneumovirus research. <i>Journal of Clinical Virology</i> , 2012, 53, 97-105.	3.1	122

#	ARTICLE	IF	CITATIONS
163	Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , 2012, 53, 208-213.	3.1	54
164	Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. <i>PLoS ONE</i> , 2012, 7, e38929.	2.3	45
165	Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada. <i>Emerging Infectious Diseases</i> , 2012, 18, .	3.8	7
166	Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006-2010. <i>Emerging Infectious Diseases</i> , 2012, 18, 120-124.	3.8	46
167	Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1208-1214.	4.1	61
168	Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. <i>Eurosurveillance</i> , 2012, 17, .	4.8	31
169	Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. <i>Vaccine</i> , 2011, 30, 35-41.	3.1	36
170	Parenteral Peramivir Treatment for Oseltamivir-Resistant 2009 Pandemic Influenza A H1N1 Viruses. <i>Journal of Infectious Diseases</i> , 2011, 204, 1641-1642.	3.8	11
171	Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model. <i>PLoS ONE</i> , 2011, 6, e14767.	2.3	64
172	Comparison of Pandemic and Seasonal Influenza in the Pediatric Emergency Department. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 633-639.	1.2	16
173	Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 247-255.	3.4	98
174	Systematic review of influenza resistance to the neuraminidase inhibitors. <i>BMC Infectious Diseases</i> , 2011, 11, .	2.6	180
175	Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors. <i>Journal of Infectious Diseases</i> , 2011, 203, 25-31.	3.8	150
176	Influenza Drug Resistance. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 409-422.	2.3	74
177	Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4019-4027.	4.1	33
178	Design considerations in building in silico equivalents of common experimental influenza virus assays. <i>Autoimmunity</i> , 2011, 44, 282-293.	3.1	37
179	Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) Viruses. <i>PLoS Pathogens</i> , 2011, 7, e1002431.	4.4	79
180	The 2009 Pandemic H1N1 D222G Hemagglutinin Mutation Alters Receptor Specificity and Increases Virulence in Mice but Not in Ferrets. <i>Journal of Infectious Diseases</i> , 2011, 204, 1008-1016.	3.8	38

#	ARTICLE	IF	CITATIONS
181	Implication of Uncoupling Protein 2 in Immunity to Herpes Simplex Virus Type I in Resistant and Susceptible Mouse Strains. <i>Journal of Neuroparasitology</i> , 2011, 2, 1-10.	0.0	0
182	Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis. <i>Transplantation</i> , 2010, 90, 1409-1413.	2.1	24
183	Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. <i>Antiviral Therapy</i> , 2010, 15, 579-586.	1.9	17
184	Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. <i>Antiviral Research</i> , 2010, 88, 31-37.	3.8	44
185	Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. <i>Journal of Medical Virology</i> , 2010, 82, 1000-1006.	3.7	16
186	The distinguishing features of human metapneumovirus and respiratory syncytial virus. <i>Reviews in Medical Virology</i> , 2010, 20, 245-260.	6.8	87
187	Management and Prevention of Herpes Zoster: A Canadian Perspective. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21, 45-52.	4.9	17
188	Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses. <i>Journal of Infectious Diseases</i> , 2010, 201, 740-745.	3.8	126
189	Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2819-2822.	4.1	20
190	Household Transmission of the 2009 Pandemic A/H1N1 Influenza Virus: Elevated Laboratory-Confirmed Secondary Attack Rates and Evidence of Asymptomatic Infections. <i>Clinical Infectious Diseases</i> , 2010, 51, 1033-1041.	5.2	107
191	Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 201, 297-301.	3.8	26
192	Association between the 2008-09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring-Summer 2009: Four Observational Studies from Canada. <i>PLoS Medicine</i> , 2010, 7, e1000258.	8.1	278
193	Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets. <i>PLoS Pathogens</i> , 2010, 6, e1001015.	4.4	87
194	Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , 2010, 47, 321-324.	3.1	37
195	Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. <i>Journal of Clinical Virology</i> , 2010, 49, 296-298.	3.1	17
196	Disseminated Herpes Simplex Virus Type 1 Primary Infection in a Healthy Individual. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 122-125.	4.9	9
197	A Case of Disseminated Infection Caused by <i>Streptococcus equi</i> Subspecies <i>zooepidemicus</i> . <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, 59-61.	4.9	35
198	Molecular Characterization of Viruses from Clinical Respiratory Samples Producing Unidentified Cytopathic Effects in Cell Culture. <i>Viruses</i> , 2009, 1, 84-90.	3.2	5

#	ARTICLE	IF	CITATIONS
199	Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 791-793.	4.1	14
200	A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus. <i>Journal of Infectious Diseases</i> , 2009, 199, 180-183.	3.8	43
201	Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. <i>New England Journal of Medicine</i> , 2009, 361, 2296-2297.	34.6	218
202	Comparison of Automated Microarray Detection with Real-Time PCR Assays for Detection of Respiratory Viruses in Specimens Obtained from Children. <i>Journal of Clinical Microbiology</i> , 2009, 47, 743-750.	4.0	96
203	The Need for Validation of Statistical Methods for Estimating Respiratory Virus-Attributable Hospitalization. <i>American Journal of Epidemiology</i> , 2009, 170, 925-936.	3.3	42
204	Detection of human metapneumovirus antigens in nasopharyngeal aspirates using an enzyme immunoassay. <i>Journal of Clinical Virology</i> , 2009, 44, 88-90.	3.1	14
205	Influenza virus shedding—Excretion patterns and effects of antiviral treatment. <i>Journal of Clinical Virology</i> , 2009, 44, 255-261.	3.1	37
206	Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. <i>Journal of Clinical Virology</i> , 2009, 46, 129-133.	3.1	100
207	Épidémiologie et impact clinique des nouveaux virus respiratoires. <i>Revue Des Maladies Respiratoires Actualites</i> , 2009, 1, S88-S89.	0.0	0
208	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , 2009, 14, 697-704.	1.9	101
209	Human parechovirus causes encephalitis with white matter injury in neonates. <i>Annals of Neurology</i> , 2008, 64, 266-273.	6.6	291
210	Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. <i>Antiviral Research</i> , 2008, 77, 163-166.	3.8	61
211	Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes. <i>Antiviral Research</i> , 2008, 77, 77-80.	3.8	21
212	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. <i>Journal of Clinical Virology</i> , 2008, 42, 52-57.	3.1	42
213	Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. <i>Vaccine</i> , 2008, 26, 3395-3403.	3.1	180
214	Effect of Pretreatment with Toll-Like Receptor Agonists in a Mouse Model of Herpes Simplex Virus Type 1 Encephalitis. <i>Journal of Infectious Diseases</i> , 2008, 198, 664-672.	3.8	63
215	Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 279-287.	4.1	60
216	Amphipathic DNA Polymers Exhibit Antiherpetic Activity In Vitro and In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2727-2733.	4.1	34

#	ARTICLE	IF	CITATIONS
217	Human Bocavirus Infections in Hospitalized Children and Adults. <i>Emerging Infectious Diseases</i> , 2008, 14, 217-221.	3.8	151
218	Persistent Human Metapneumovirus Infection in Immunocompromised Child. <i>Emerging Infectious Diseases</i> , 2008, 14, 854-856.	3.8	19
219	New Saffold Cardioviruses in 3 Children, Canada. <i>Emerging Infectious Diseases</i> , 2008, 14, 834-836.	3.8	79
220	A Review of Influenza Vaccine Immunogenicity and Efficacy in HIV-Infected Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2008, 19, 419-423.	4.9	15
221	Inhibition of Human Metapneumovirus Replication by Small Interfering RNA. <i>Antiviral Therapy</i> , 2008, 13, 821-832.	1.9	27
222	The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice. <i>Antiviral Therapy</i> , 2008, 13, 39-46.	1.9	29
223	Human Metapneumovirus. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 213-221.	2.3	54
224	Tumor Necrosis Factor- α and Interleukin-1 β Play a Critical Role in the Resistance against Lethal Herpes Simplex Virus Encephalitis. <i>Journal of Infectious Diseases</i> , 2007, 196, 853-860.	3.8	151
225	Development of a Serological Assay Based on a Synthetic Peptide Selected from the VP0 Capsid Protein for Detection of Human Parechoviruses. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2037-2039.	4.0	24
226	An Outbreak of Severe Respiratory Tract Infection Due to Human Metapneumovirus in a Long-Term Care Facility. <i>Clinical Infectious Diseases</i> , 2007, 44, 1152-1158.	5.2	207
227	Delayed but Not Early Glucocorticoid Treatment Protects the Host during Experimental Herpes Simplex Virus Encephalitis in Mice. <i>Journal of Infectious Diseases</i> , 2007, 195, 817-825.	3.8	74
228	Influenzavirus Infection Is a Primary Cause of Febrile Respiratory Illness in HIV-Infected Adults, Despite Vaccination. <i>Clinical Infectious Diseases</i> , 2007, 45, 234-240.	5.2	85
229	Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. <i>Vaccine</i> , 2007, 25, 5034-5040.	3.1	64
230	Antibiotic use in children is not influenced by the result of rapid antigen detection test for the respiratory syncytial virus. <i>Journal of Clinical Virology</i> , 2007, 39, 169-174.	3.1	20
231	WU Polyomavirus in Children, Canada. <i>Emerging Infectious Diseases</i> , 2007, 13, 1939-1941.	3.8	81
232	A comparative analysis of strategies for isolation of matrix vesicles. <i>Analytical Biochemistry</i> , 2007, 361, 176-182.	2.4	37
233	Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. <i>Antiviral Research</i> , 2007, 74, 159-162.	3.8	62
234	Amphipathic DNA Polymers are Candidate Vaginal Microbicides and Block Herpes Simplex Virus Binding, Entry and Viral Gene Expression. <i>Antiviral Therapy</i> , 2007, 12, 1147-1156.	1.9	33

#	ARTICLE	IF	CITATIONS
235	Influenza Virus Susceptibility and Resistance to Oseltamivir. <i>Antiviral Therapy</i> , 2007, 12, 603-616.	1.9	158
236	Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet. <i>Journal of Virology</i> , 2006, 80, 1440-1450.	3.6	29
237	Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient. <i>Journal of Clinical Virology</i> , 2006, 37, 34-37.	3.1	3
238	Multi-year study of human metapneumovirus infection at a large US Midwestern Medical Referral Center. <i>Journal of Clinical Virology</i> , 2006, 37, 269-276.	3.1	35
239	Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. <i>Journal of Clinical Virology</i> , 2006, 37, 248-251.	3.1	21
240	Human Metapneumovirus, Peru. <i>Emerging Infectious Diseases</i> , 2006, 12, 347-350.	3.8	51
241	Human Parechovirus Infections in Canada. <i>Emerging Infectious Diseases</i> , 2006, 12, 969-975.	3.8	117
242	Treatment of respiratory virus infections. <i>Antiviral Research</i> , 2006, 70, 1-16.	3.8	66
243	Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children over 2 Winter Seasons. <i>Journal of Infectious Diseases</i> , 2006, 193, 54-58.	3.8	97
244	Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome. <i>Journal of Infectious Diseases</i> , 2006, 194, 579-583.	3.8	27
245	Effect of Ribavirin and Glucocorticoid Treatment in a Mouse Model of Human Metapneumovirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 774-777.	4.1	119
246	Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3889-3892.	4.1	28
247	Cytomegalovirus Ventriculoencephalitis in a Peripheral Blood Stem Cell Transplant Recipient. <i>Clinical Infectious Diseases</i> , 2006, 42, e26-e29.	5.2	32
248	Human Metapneumovirus Infection Induces Long-Term Pulmonary Inflammation Associated with Airway Obstruction and Hyperresponsiveness in Mice. <i>Journal of Infectious Diseases</i> , 2006, 193, 1634-1642.	3.8	94
249	Characterization of Multidrug-Resistant Influenza A/H3N2 Viruses Shed during 1 Year by an Immunocompromised Child. <i>Clinical Infectious Diseases</i> , 2006, 43, 1555-1561.	5.2	182
250	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds. <i>Antiviral Therapy</i> , 2006, 11, 971-976.	1.9	160
251	Infections by Human Coronavirus-NL in Hospitalized Children. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 1045-1048.	1.2	37
252	Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. <i>Transplant Infectious Disease</i> , 2005, 7, 166-170.	2.2	80

#	ARTICLE	IF	CITATIONS
253	A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1462-1468.	4.5	93
254	Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. <i>Journal of Medical Virology</i> , 2005, 77, 425-429.	3.7	61
255	Molecular characterization of a Canadian human parechovirus (HPeV)-3 isolate and its relationship to other HPeVs. <i>Journal of Medical Virology</i> , 2005, 77, 566-570.	3.7	45
256	Human Parechovirus 3 and Neonatal Infections. <i>Emerging Infectious Diseases</i> , 2005, 11, 103-107.	3.8	201
257	Human Metapneumovirus Genetic Variability, South Africa. <i>Emerging Infectious Diseases</i> , 2005, 11, 1074-1078.	3.8	69
258	Analysis of Replication Kinetics of the Human Metapneumovirus in Different Cell Lines by Real-Time PCR. <i>Journal of Clinical Microbiology</i> , 2005, 43, 488-490.	4.0	55
259	New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4860-4866.	4.1	28
260	Human Cytomegalovirus Resistance to Antiviral Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 873-883.	4.1	213
261	Human Metapneumovirus Infection in Adults with Community-Acquired Pneumonia and Exacerbation of Chronic Obstructive Pulmonary Disease. <i>Clinical Infectious Diseases</i> , 2005, 41, 498-502.	5.2	129
262	Development and Validation of an Enzyme-Linked Immunosorbent Assay for Human Metapneumovirus Serology Based on a Recombinant Viral Protein. <i>Vaccine Journal</i> , 2005, 12, 249-253.	3.1	47
263	Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 556-559.	4.1	180
264	Human Metapneumovirus. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, S203-S207.	1.2	42
265	Influenza virus activates human immunodeficiency virus type-1 gene expression in human CD4-expressing T cells through an NF- κ B-dependent pathway. <i>Clinical Immunology</i> , 2005, 114, 190-198.	2.7	2
266	Global Genetic Diversity of Human Metapneumovirus Fusion Gene. <i>Emerging Infectious Diseases</i> , 2004, 10, 1154-1157.	3.8	136
267	Absence of Cytomegalovirus Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2004, 189, 1615-1618.	3.8	161
268	Human Metapneumovirus: A New Player among Respiratory Viruses. <i>Clinical Infectious Diseases</i> , 2004, 38, 983-990.	5.2	189
269	Comparative Evaluation of Three Serological Methods for Detection of Human Herpesvirus 8-Specific Antibodies in Canadian Allogeneic Stem Cell Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2663-2667.	4.0	23
270	Multiplex Real-Time PCR Assay for Detection of Influenza and Human Respiratory Syncytial Viruses. <i>Journal of Clinical Microbiology</i> , 2004, 42, 45-51.	4.0	139

#	ARTICLE	IF	CITATIONS
271	A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus. <i>Antiviral Therapy</i> , 2004, 9, 577-581.	1.9	80
272	Title is missing!. <i>Virus Genes</i> , 2003, 27, 125-135.	1.9	6
273	Genetic diversity between human metapneumovirus subgroups. <i>Virology</i> , 2003, 315, 1-9.	2.3	240
274	Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. <i>Antiviral Research</i> , 2003, 60, 51-59.	3.8	211
275	Inâ€f vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical gutta-percha condensation techniques. <i>International Endodontic Journal</i> , 2003, 36, 367-371.	6.7	30
276	Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. <i>Virus Research</i> , 2003, 93, 51-62.	2.6	121
277	Human Metapneumovirus-Associated Lower Respiratory Tract Infections among Hospitalized Human Immunodeficiency Virus Type 1 (HIV-1)-Infected and HIV-1-Uninfected African Infants. <i>Clinical Infectious Diseases</i> , 2003, 37, 1705-1710.	5.2	118
278	Cytomegalovirus (CMV) Glycoprotein B Genotypes and Response to Antiviral Therapy, in Solidâ€Organâ€ Transplant Recipients with CMV Disease. <i>Journal of Infectious Diseases</i> , 2003, 188, 581-584.	3.8	75
279	Evaluation of Susceptibility of Human Herpesvirus 8 to Antiviral Drugs by Quantitative Real-Time PCR. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3897-3900.	4.0	38
280	Comparative Evaluation of Real-Time PCR Assays for Detection of the Human Metapneumovirus. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3631-3635.	4.0	123
281	Quantification of the Influenza Virus Load by Realâ€Time Polymerase Chain Reaction in Nasopharyngeal Swabs of Patients Treated with Oseltamivir. <i>Journal of Infectious Diseases</i> , 2003, 188, 578-580.	3.8	42
282	Discordant phenotypes and genotypes of Cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. <i>Aids</i> , 2003, 17, 337-341.	2.5	19
283	Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids. <i>Journal of Virology</i> , 2003, 77, 7820-7829.	3.6	88
284	Human Metapneumovirus Infections in Hospitalized Children1. <i>Emerging Infectious Diseases</i> , 2003, 9, 634-640.	3.8	423
285	Syncytium Formation and HIV-1 Replication Are Both Accentuated by Purified Influenza and Virus-associated Neuraminidase. <i>Journal of Biological Chemistry</i> , 2002, 277, 9825-9833.	2.2	9
286	Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene. <i>Journal of Infectious Diseases</i> , 2002, 186, 1074-1080.	3.8	57
287	Prolonged Excretion of Amantadine-Resistant Influenza A Virus Quasi Species after Cessation of Antiviral Therapy in an Immunocompromised Patient. <i>Clinical Infectious Diseases</i> , 2002, 34, e23-e25.	5.2	73
288	Cytomegalovirus (CMV) Virus Load Kinetics to Predict Recurrent Disease in Solidâ€Organ Transplant Patients with CMV Disease. <i>Journal of Infectious Diseases</i> , 2002, 186, 829-833.	3.8	183

#	ARTICLE	IF	CITATIONS
289	Role of Picornaviruses in Flu-Like Illnesses of Adults Enrolled in an Oseltamivir Treatment Study Who Had No Evidence of Influenza Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 330-334.	4.0	20
290	Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratory Tract Infections in All Age Groups. <i>Journal of Infectious Diseases</i> , 2002, 186, 1330-1334.	3.8	580
291	Characterization of Human Metapneumoviruses Isolated from Patients in North America. <i>Journal of Infectious Diseases</i> , 2002, 185, 1660-1663.	3.8	388
292	Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. <i>Drug Resistance Updates</i> , 2002, 5, 88-114.	19.2	295
293	Respiratory Tract Reinfections by the New Human Metapneumovirus in an Immunocompromised Child. <i>Emerging Infectious Diseases</i> , 2002, 8, 976-978.	3.8	216
294	Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. <i>Antiviral Research</i> , 2002, 54, 143-147.	3.8	65
295	Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. <i>Journal of Medical Virology</i> , 2002, 67, 589-595.	3.7	47
296	Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castlemans disease. <i>Journal of Medical Virology</i> , 2002, 68, 399-403.	3.7	42
297	Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain. <i>European Journal of Neuroscience</i> , 2002, 16, 29-43.	3.5	47
298	Molecular evolution of influenza A/H3N2 viruses in the province of Qubec (Canada) during the 1997-2000 period. <i>Virus Research</i> , 2001, 77, 89-96.	2.6	10
299	Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) Resistance following Preemptive GCV Therapy in Allogeneic Stem Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3669-3671.	4.1	41
300	Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues. <i>Journal of Virology</i> , 2001, 75, 3105-3110.	3.6	59
301	Evaluation of a Rapid Optical Immunoassay for Influenza Viruses (FLU OIA Test) in Comparison with Cell Culture and Reverse Transcription-PCR. <i>Journal of Clinical Microbiology</i> , 2001, 39, 730-732.	4.0	81
302	Rate of Emergence of Cytomegalovirus (CMV) Mutations in Leukocytes of Patients with Acquired Immunodeficiency Syndrome Who Are Receiving Valganciclovir as Induction and Maintenance Therapy for CMV Retinitis. <i>Journal of Infectious Diseases</i> , 2001, 184, 1598-1602.	3.8	127
303	Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS Patients on highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1907-1910.	2.5	55
304	Reply. <i>Journal of Infectious Diseases</i> , 2000, 182, 378-379.	3.8	1
305	Clearance of Cytomegalovirus Viremia after Initiation of Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2000, 181, 1216-1217.	3.8	10
306	Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults. <i>Journal of Infectious Diseases</i> , 2000, 181, 1471-1474.	3.8	73

#	ARTICLE	IF	CITATIONS
307	Predicting Influenza Infections during Epidemics with Use of a Clinical Case Definition. <i>Clinical Infectious Diseases</i> , 2000, 31, 1166-1169.	5.2	314
308	Quantitative Analysis of Cytomegalovirus (CMV) Viremia Using the pp65 Antigenemia Assay and the COBAS AMPLICOR CMV MONITOR PCR Test after Blood and Marrow Allogeneic Transplantation. <i>Journal of Clinical Microbiology</i> , 2000, 38, 4356-4360.	4.0	59
309	Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed. <i>Journal of Infectious Diseases</i> , 1999, 180, 487-490.	3.8	97
310	Expression of the Late Cytomegalovirus (CMV) pp150 Transcript in Leukocytes of AIDS Patients Is Associated with a High Viral DNA Load in Leukocytes and Presence of CMV DNA in Plasma. <i>Journal of Infectious Diseases</i> , 1999, 179, 1101-1107.	3.8	20
311	Human cytomegalovirus glycoprotein B genotypes in blood of AIDS patients: Lack of association with either the viral DNA load in leukocytes or presence of retinitis. , 1999, 59, 98-103.		29
312	Human Herpesvirus 8 DNA Load in Leukocytes of Human Immunodeficiency Virus-Infected Subjects: Correlation with the Presence of Kaposi's Sarcoma and Response to Anticytomegalovirus Therapy. Antimicrobial Agents and Chemotherapy, 1999, 43, 377-380.	4.1	38
313	Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 1998, 178, 297-303.	3.8	185
314	Comparative Evaluation of the Cytomegalovirus DNA Load in Polymorphonuclear Leukocytes and Plasma of Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Infectious Diseases</i> , 1998, 177, 355-360.	3.8	57
315	Reply. <i>Journal of Infectious Diseases</i> , 1998, 178, 1545-1546.	3.8	0
316	Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. <i>Aids</i> , 1998, 12, 125-129.	2.5	46
317	Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. <i>Clinical Microbiology Reviews</i> , 1998, 11, 533-554.	16.8	390
318	Evaluation of the AMPLICOR Cytomegalovirus Test with Specimens from Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2509-2513.	4.0	41
319	Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 1997, 175, 1087-1092.	3.8	153
320	A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS. <i>Aids</i> , 1997, 11, 867-873.	2.5	22
321	Quantitation of Cytomegalovirus DNA and Characterization of Viral Gene Expression in Bronchoalveolar Cells of Infected Patients with and without Pneumonitis. <i>Journal of Infectious Diseases</i> , 1996, 173, 1304-1312.	3.8	42
322	Detection of Ganciclovir Resistance Mutations and Quantitation of Cytomegalovirus (CMV) DNA in Leukocytes of Patients with Fatal Disseminated CMV Disease. <i>Journal of Infectious Diseases</i> , 1996, 173, 523-528.	3.8	95
323	Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system. <i>Journal of Virological Methods</i> , 1995, 51, 329-342.	1.7	38
324	Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS. <i>Journal of Infectious Diseases</i> , 1994, 170, 68-75.	3.8	128

#	ARTICLE	IF	CITATIONS
325	Ganciclovir Susceptibilities of Cytomegalovirus (CMV) Isolates from Solid Organ Transplant Recipients with CMV Viremia after Antiviral Prophylaxis. <i>Journal of Infectious Diseases</i> , 1993, 168, 332-335.	3.8	82
326	Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 357-359.	4.1	27
327	Experimental study of Cu ²⁺ /PbCl ₂ , Cu ²⁺ /NaF, Ag ⁺ /PbCl ₂ , and Ag ⁺ /NaF cermet thin films. <i>Applied Optics</i> , 1989, 28, 717.	1.8	7
328	Synthesis of gradient-index profiles corresponding to spectral reflectance derived by inverse Fourier transform. <i>Applied Optics</i> , 1987, 26, 4209.	1.8	34
329	Influence of surface effects in the determination of the optical constants of Cu ²⁺ /Pb ₂ cermet films. <i>Applied Optics</i> , 1984, 23, 4245.	1.8	4
330	Maxwell-Garnett theory extended for Cu ²⁺ /Pb ₂ cermets. <i>Applied Optics</i> , 1984, 23, 4494.	1.8	11
331	Metal ²⁺ /dielectric photosystems. <i>Applied Optics</i> , 1978, 17, 736.	1.8	1
332	Use of a Fresnel zone plate for optical image formation with short wavelength radiations. <i>Applied Optics</i> , 1977, 16, 1070.	1.8	4
333	Fabrication of metal-dielectric interference filters: a simple method. <i>Applied Optics</i> , 1977, 16, 1890.	1.8	2
334	The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study. <i>JMIR Public Health and Surveillance</i> , 0, 10, e40792.	4.8	21
335	Fitness of SARS-CoV-2 Omicron Subvariants in Respiratory and Gastrointestinal Cell Lines as Determined by Reverse-Transcription Droplet Digital PCR and Whole-Genome Sequencing. <i>Journal of Infectious Diseases</i> , 0, 232, e656-e660.	3.8	0
336	Is COVID-19 Associated With an Increased Risk of Subsequent Upper Respiratory Tract Infections in Adults? A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 0, 12, .	0.8	0
337	Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3. <i>Reviews in Medical Virology</i> , 0, 35, .	6.8	2
338	Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection. <i>Antiviral Therapy</i> , 0, 30, .	1.9	0
339	P-1552. First-in-Human Challenge Study with Human Metapneumovirus A2: Characterization of Clinical Outcomes and Immunological Correlates. <i>Open Forum Infectious Diseases</i> , 0, 13, .	0.8	0